The brochure provides you with an overview of the key features and benefits of our next-generation Biomarker Discovery solutions. In addition, the brochure elaborates on our deep and reproducible proteome quantification and analysis. Finally, it digs into how we identify the most promising and actionable biomarkers for research and clinical decision-making.
Presenter: Yuehan Feng
Authors: Marco Tognetti, Christoph Messner, Roland Bruderer, Dominique Kamber, Jacqueline Darrow, Alexandra Lewis, Jakob Vowinckel, Abhay Moghekar, Lukas Reiter, Yuehan Feng
In collaboration with with the Johns Hopkins University School of Medicine
Overview: Since the genome remains invariant throughout the lifespan, it is essential to understand the effects of aging on the proteome, as proteins play an integral role in all cellular functions and mediate the effects of epigenetic alterations. At the SfN Annual Meeting we presented a study in collaboration with Johns Hopkins University School of Medicine on proteomic profiling of biomarker candidates for Alzheimer’s Disease in plasma and CSF with our TrueDiscovery™ platform.
Download the poster to learn more about how the quantitative proteoform map is linked to healthy and pathological aging, providing a rich resource for therapeutic target discovery.
Presenter: Lukas Reiter
Date: November 7
The poster discusses how plasma samples were measured using Biognosys’ TrueDiscovery workflow. Due to the particular protein abundance distribution in human plasma substantial improvements in proteome depth could be achieved allowing to profile more than 4000 proteins using a single shot mass spectrometry workflow.
E-Poster #MP 016 presented at ASMS 2021
Presenter: Christopher Below
Session: Biomarkers: Quantitative Analysis
Date: Monday, November 1
E-Poster presented at HUPO Reconnect 2021
Presenter: Yuehan Feng
Abstract Number: 162
Topic: 01. Brain Rewiring in Neurological Disorders
Veronica G. Anania, Kebing Yu, Francesco Pingitore, Qingling Li, Christopher M. Rose, Peter Liu, Wendy Sandoval, Ann E. Herman, Jennie R. Lill, and W. Rodney Mathews. Journal of Proteome Research.
Lupus nephritis (LN) is a severe clinical manifestation of systemic lupus erythematosus (SLE) associated with significant morbidity and mortality. Assessment of severity and activity of renal involvement in SLE requires a kidney biopsy, an invasive procedure with limited prognostic value. Noninvasive biomarkers are needed to inform treatment decisions and to monitor disease activity. Proteinuria is associated with disease progression in LN; however, the composition of the LN urinary proteome remains incompletely characterized. To address this, we profiled LN urine samples using complementary mass spectrometry-based methods: protein gel fractionation, chemical labeling using tandem mass tags, and data-independent acquisition. Combining results from these approaches yielded quantitative information on 2573 unique proteins in urine from LN patients. A multiple-reaction monitoring (MRM) method was established to confirm eight proteins in an independent cohort of LN patients, and seven proteins (transferrin, α-2-macroglobulin, haptoglobin, afamin, α-1-antitrypsin, vimentin, and ceruloplasmin) were confirmed to be elevated in LN urine compared to healthy controls. In this study, we demonstrate that deep mass spectrometry profiling of a small number of patient samples can identify high-quality biomarkers that replicate in an independent LN disease cohort. These biomarkers are being used to inform clinical biomarker strategies to support longitudinal and interventional studies focused on evaluating disease progression and treatment efficacy of novel LN therapeutics.
Presenter: Roland Bruderer
Date: November 7
Alterations in biofluid proteomes are powerful molecular biosignatures for the screening and diagnosis of bladder and kidney-related diseases. At HUPO 2022, Roland Bruderer presented a poster on how we identified actionable biomarkers for bladder cancer and chronic kidney disease in urine with our TrueDiscovery™ platform for deep unbiased mass-spectrometry-based proteomics.
From the total of 12,617 proteins identified in the urine samples, we revealed changes in proteins involved in programmed cell death, telomerase organization, keratinocyte, and epidermal cell differentiation, as well as inflammation markers and previously described markers such as urokinase plasminogen activator surface receptor (UPAR). Of the altered proteins analyzed, 23 significantly differentiated the pathophysiological conditions. Download the poster to discover more.
Presenter: Roland Bruderer
Date: Monday, June 5
Topic area: Biomarkers: Quantitative Analysis I
Presenter: Ino Karemaker
Date: November 5
The poster discusses plasma and CSF data collected with our TrueDiscovery™ platform in collaboration with The Johns Hopkins University School of Medicine in plasma.
Out of the almost 6,000 proteins identified in CSF and more than 3,000 in plasma from young healthy control subjects, patients with mild cognitive impairment, age-matched healthy controls, and Alzheimer’s patients, we were able to generate a comprehensive and quantitative map of proteomes linked to healthy and pathological aging. Download the poster to discover more.
Biognosys AG
Wagistrasse 21
8952 Schlieren
Switzerland
Phone: +41 44 738 20 40
US Offices
Biognosys Inc
70 Bridge St, Suite 104
Newton, MA 02458
United States
